Blair William & Co. IL Has $58.03 Million Stake in Pfizer Inc. (NYSE:PFE)

Key Points

• Blair William & Co. IL increased its stake in Pfizer Inc. by 0.9% during Q1, owning 2,290,198 shares valued at approximately $58 million.
• Pfizer's quarterly dividend of $0.43 per share represents an annual yield of 7.3% and has a payout ratio of 124.64%.
• Institutional investors now hold 68.36% of Pfizer's stock, indicating strong institutional support for the biopharmaceutical company.

Blair William & Co. IL raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 0.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,290,198 shares of the biopharmaceutical company's stock after acquiring an additional 20,179 shares during the quarter. Blair William & Co. IL's holdings in Pfizer were worth $58,034,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Northern Trust Corp lifted its holdings in Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after purchasing an additional 4,167,222 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after purchasing an additional 1,333,740 shares during the period. Invesco Ltd. raised its position in shares of Pfizer by 9.6% in the fourth quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company's stock valued at $781,524,000 after purchasing an additional 2,579,455 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Pfizer by 22.2% during the 1st quarter. Federated Hermes Inc. now owns 17,592,709 shares of the biopharmaceutical company's stock worth $445,799,000 after buying an additional 3,201,087 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.49 on Monday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company has a market cap of $133.55 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.85 and a beta of 0.52. The firm has a 50 day simple moving average of $24.36 and a 200 day simple moving average of $24.55.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. The Goldman Sachs Group increased their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Leerink Partners dropped their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. TD Cowen decreased their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. Finally, Citigroup lifted their price objective on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.